SecBot SecBot
SECBOTREPLAY Home › Report › OCUL

OCUL · Ocular Therapeutix filed an 8-K reporting the formal appointment of…

OCULAR THERAPEUTIX, INC · 8-K filed Jun 12, 2026 at 16:23 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 12, 2026 at 16:23 ET

Ocular Therapeutix filed an 8-K reporting the formal appointment of Jason Robins as CFO (previously interim) and stockholder approval of a 10,000,000-share increase to the 2021 Stock Incentive Plan at the 2026 Annual Meeting. The CFO appointment is a routine transition with no red flags, and the equity plan increase is standard for a biotech. No material financial data or guidance was provided.

  • Jason Robins appointed CFO on June 10, 2026, after serving as interim CFO since January 20, 2026.
  • Robins' annual base salary increased to $535,100 effective July 1, 2026, with a target bonus of 45% of base salary.
  • Robins received a stock option for 14,024 shares and an RSU award for 15,441 shares, both subject to vesting.
  • Stockholders approved Amendment No. 5 to the 2021 Stock Incentive Plan, increasing authorized shares by 10,000,000.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access